- Home
- SNTG vs TOVX Comparison
SNTG vs TOVX Comparison
Compare SNTG & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | TOVX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 7.3M |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SNTG | TOVX |
|---|---|---|
| Price | $2.07 | $0.21 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 11.0M |
| Earning Date | 04-27-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.17 |
| 52 Week High | $12.70 | $2.03 |
Technical Indicators
Market Signals| Indicator | SNTG | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 47.86 |
| Support Level | $1.87 | $0.19 |
| Resistance Level | $2.11 | $0.26 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 42.86 | 46.86 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.